By Connor Hart
Arcutis Biotherapeutics promoted Latha Vairavan to chief financial officer, effective immediately, prior to the filing of the company's upcoming first-quarter financial report.
Vairavan most recently was the company's vice president of finance and corporate controller, overseeing daily accounting operations and ensuring compliance with financial, accounting and income tax regulations, the company said Thursday.
She joined the company in March 2020, having previously held roles of increasing responsibility at biopharmaceutical company Amgen.
As CFO of Arcutis, Vairavan's annual base salary will increase to $450,000, according to a filing with the Securities and Exchange Commission. She will additionally be eligible for an annual bonus up to 67.5% of her annual salary, as well as stock options and other benefits.
Vairavan will succeed David Topper, who plans to retire. Topper will provide transition support through his departure from the company, scheduled for May 15.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 10, 2025 17:41 ET (21:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.